Lexeo Therapeutics, Inc. Common Stock (LXEO) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Lexeo Therapeutics, Inc. Common Stock (LXEO) Earnings Overview
As of June 23, 2026, Lexeo Therapeutics, Inc. Common Stock (LXEO) reported trailing twelve-month net income of -$88M, reflecting +39.8% year-over-year growth. The company earned $-1.08 per diluted share over the past four quarters.
Looking at the long-term picture, LXEO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2020.
Lexeo Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$209M net income), KRYS ($225M net income, 52.6% margin), SGMO (-$123M net income, -310.8% margin), LXEO has comparable earnings metrics. Compare LXEO vs RCKT →
LXEO Earnings vs Peers
Earnings metrics vs comparable public companies
LXEO Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$100M | -1.7% | -$109M | $-1.86 | - | - |
| 2024 | -$98M | -48.1% | -$106M | $-3.09 | - | - |
| 2023 | -$66M | -12.0% | -$69M | $-2.49 | - | - |
| 2022 | -$59M | -17.1% | -$61M | $-2.40 | -9063.8% | -9252.1% |
| 2021 | -$51M | -882.4% | -$51M | $-2.01 | -3055.0% | -3055.9% |
| 2020 | -$5M | - | -$5M | $-0.20 | -993.8% | -884.9% |
Download Data
Export LXEO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LXEO — Frequently Asked Questions
Quick answers to the most common questions about buying LXEO stock.
What is LXEO earnings per share (EPS)?
LXEO trailing twelve-month (TTM) diluted EPS is $-1.08, reflecting +39.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Lexeo Therapeutics, Inc. Common Stock's net income?
Lexeo Therapeutics, Inc. Common Stock (LXEO) trailing twelve-month net income is $-88M as of 2025. Earnings grew +39.8% year-over-year.
Is LXEO profitable?
LXEO is not currently profitable on a TTM basis, reporting a net loss of $-88M. Net margin is N/A. Investors should monitor for a return to profitability.
What is LXEO's earnings growth rate?
LXEO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are LXEO's profit margins?
Lexeo Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -55.0%.
Is LXEO growing earnings?
Yes, LXEO earnings are accelerating — EPS growth of +39.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-88M. Earnings momentum is strengthening.
What was LXEO's best earnings year?
Lexeo Therapeutics, Inc. Common Stock's highest annual net income on record is $-5M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were LXEO's earnings last quarter?
LXEO's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-0.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.